Drug
Vedolizumab clinical trials
Also written Entyvio, MLN0002 and LDP-02.
Keep track of what changes. Save the vedolizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Entyvio
- 40
Studies by the year they started
88 studies that test it; most in 2017 (13)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2014 | 5 |
| 2015 | 5 |
| 2016 | 11 |
| 2017 | 13 |
| 2018 | 11 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 7 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 6 |
| 2025 | 7 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 51 · Other 37
Takeda (39) · Millennium Pharmaceuticals, Inc. (10) · M.D. Anderson Cancer Center (2) · Alimentiv Inc. (2) · ANRS, Emerging Infectious Diseases (2) · Geert D'Haens (2) · Centre Hospitalier Universitaire de Saint Etienne (2) · AbbVie (1)
Often tested with
Tested in the same studies.
Infliximab (3) · Adalimumab (2) · Cyclophosphamide (2) · Risankizumab (1) · Mirikizumab (1) · Ustekinumab (1) · Methotrexate (1) · Tofacitinib (1)
Studies
Open first, then newest update. How each study uses vedolizumab is read from its arms, and is right about nine times in ten.
Testing it · 88
- A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community SettingRecruitingPhase 4TakedaNCT06581328Written as Vedolizumab IV
- A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)RecruitingPhase 3TakedaNCT06405087Written as Vedolizumab SC
- A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)RecruitingPhase 4TakedaNCT06095128Written as Vedolizumab
- Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With CancerRecruitingPhase 2/3AHS Cancer Control AlbertaNCT06337695Written as Vedolizumab
- A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's DiseaseRecruitingPhase 3TakedaNCT06100289Written as Vedolizumab IV
- A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic PouchitisRecruitingPhase 3TakedaNCT06443502Written as Vedolizumab
- Autologous Stem Cell Transplant for Crohn's DiseaseRecruitingPhase 2Aaron EtraNCT03219359Written as Vedolizumab
- Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With CancerRecruitingPhase 1M.D. Anderson Cancer CenterNCT03819296Written as Vedolizumab
- Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity ConditioningRecruitingPhase 2City of Hope Medical CenterNCT06815003Written as Vedolizumab
- A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)RecruitingPhase 3TakedaNCT05442567Written as Vedolizumab IV
- A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)RecruitingPhase 3TakedaNCT04779320Written as Vedolizumab IV
- Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.RecruitingPhase 4Centre Hospitalier Universitaire de Saint EtienneNCT06180382Written as Vedolizumab
- Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative ColitisRecruitingPhase 2Odyssey TherapeuticsNCT06850727Written as Vedolizumab
- VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's DiseaseRecruitingPhase 4Alimentiv Inc.NCT06257706Written as Vedolizumab
- A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's DiseaseRecruitingPhase 3TakedaNCT05837897Written as Vedolizumab IV
- Early Vedolizumab as First-Line for Immune-Related Colitis Therapy TrialRecruitingPhase 2Shilpa Grover, MD, MPHNCT06841705Written as Vedolizumab 300 MG Injection [Entyvio]
- Study of the Effect of Vedolizumab on Intestinal Microecological Changes and Its Efficacy in the Treatment of Ulcerative ColitisRecruitingPhase 4Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05481619Written as Vedolizumab
- Subcutaneous Interval Lengthening of Vedolizumab for Economic ResearchRecruitingPhase 4Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)NCT06584162Written as Vedolizumab Injection
- Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal InvolvementRecruitingPhase 4The First Affiliated Hospital of Soochow UniversityNCT06066840Written as Vedolizumab
- Vedolizumab Treatment in Antiretroviral Drug Treated Chronic HIV InfectionRecruitingPhase 2Ottawa Hospital Research InstituteNCT03147859Written as Vedolizumab (brand name Entyvio)
See all 88 studies that test vedolizumab →
Given in every arm · 10 — vedolizumab is usual care beside what is tested
- Combination CurQD and Vedolizumab in Ulcerative ColitisNot yet recruitingPhase 4Ryan C UngaroNCT07665294Written as Vedolizumab
- A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's DiseaseRecruitingPhase 3TakedaNCT06227910Written as Vedolizumab
- Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative ColitisRecruitingNot applicableSixth Affiliated Hospital, Sun Yat-sen UniversityNCT06095596Written as Vedolizumab
- The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative ColitisRecruitingPhase 4Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06609447Written as Vedolizumab
- A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's DiseaseActive, not recruitingPhase 4TakedaNCT06045754Written as Vedolizumab
- Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative ColitisCompletedPhase 4Sixth Affiliated Hospital, Sun Yat-sen UniversityNCT05205603Written as Vedolizumab
- Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1DCompletedEarly Phase 1Benaroya Research InstituteNCT05281614Written as Vedolizumab
- Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UCTerminatedPhase 3Medical College of WisconsinNCT02954159Written as Vedolizumab
- Synergistic Effect of Vedolizumab and PentoxifyllineCompletedEarly Phase 1University of MiamiNCT02953275Written as vedolizumab
- Corticosteroids With Vedolizumab in Crohn's DiseaseTerminatedPhase 4Icahn School of Medicine at Mount SinaiNCT02324699Written as Vedolizumab
As the comparator · 5 — what is tested is compared with vedolizumab
- PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid ExposureNot yet recruitingPhase 2Therakos LLCNCT07619898Written as Vedolizumab
- Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and EntyvioTerminatedPhase 3Alvotech Swiss AGNCT06570772Written as Vedolizumab
- EPIC- Extracorporeal Photopheresis (ECP) for Immune-related ColitisWithdrawnPhase 2Therakos LLCNCT06646016Written as Vedolizumab
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)CompletedPhase 2Genentech, Inc.NCT03558152Written as Vedolizumab
- A Study of Mirikizumab (LY3074828) in Participants With Ulcerative ColitisWithdrawnPhase 3Eli Lilly and CompanyNCT04469062Written as Vedolizumab IV
Codes
What other systems call vedolizumab · ClinicalTrials.gg INT005492
- MeSH (NLM) C543529vedolizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 9RV78Q2002VEDOLIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1538097Confirmed FDA, Wikidata
- Wikidata Q7918002vedolizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95798VedolizumabOne source FDA
- DrugBank DB09033One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C543529 | vedolizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 9RV78Q2002 | VEDOLIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1538097 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7918002 | vedolizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95798 | Vedolizumab | One source FDA |
| DrugBank | DB09033 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.